The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 4%. As of press release, it had risen 4.04% to HK$40.68, with a turnover of HK$278 million.

According to the news, Insilicon Smart announced this morning that the company has reached an early drug discovery milestone in its multi-year AI-based drug discovery cooperation with Schweier, triggering Schweier to pay a milestone payment of an undisclosed amount. This multi-year R&D cooperation plan, first announced in early 2026, has a total value of US$888 million, including US$32 million in advance payments and recent R&D milestone payments.

It is worth noting that with its AI platform and pipeline assets being widely recognized around the world, Insili Intelligence achieved total revenue of about US$106 million in the first half of this year, an increase of 287% over the previous year; at the same time, it achieved adjusted net profit of over US$51 million, ushering in the first half year of profit since listing. Up to now, Insili has nominated 11 preclinical candidate compounds (PCC) within the first 10 months of 2026, setting a new historical record for the company's annual pipeline output.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.